Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (131)	11/25/1997 1:26:00 AM
From: James Silverman	Respond to of 340

Not really a strategic advantage. Basically this change is designed to align Israeli patent rules with the rest of the world. Currently, Teva can't begin to work on a generic (for the israeli market) until its patent expires-which naturally adds to the life of the relevant patent in Israel. In the US, generic companies can work on and file ANDA's for generics before a patent expires, with approvals possible upon expiration. So in short this is just designed to conform with the US.